Tofacitinib Tablet, Film Coated
Product Images NDC 72205-140

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tofacitinib (NDC 72205-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tofacitinib-10mg-180s-cntr (Tofacitinib 10mg 180s Cntr)

Tofacitinib Tablets 10 mg film-coated tablets label for oral use, distributed by Novadoz Pharmaceuticals LLC. The label indicates 180 tablets in the package, with storage instructions at 20°C to 25°C. Manufactured by MSN Laboratories Private Limited in India. Includes NDC 72205-140-18 and barcode information.*

FDA Label Image

Tofacitinib-10mg-28s-cntr (Tofacitinib 10mg 28s Cntr)

Tofacitinib Tablets 10 mg film-coated oral tablets packaging label. The carton contains 28 tablets and is labeled for prescription only. The label shows the manufacturer as MSN Laboratories Pvt Ltd in India and distributor as Novadoz Pharmaceuticals LLC, Piscataway, NJ. It includes storage instructions and a barcode.*

FDA Label Image

Tofacitinib-10mg-60s-cntr (Tofacitinib 10mg 60s Cntr)

Label for Tofacitinib Tablets 10 mg, film-coated oral tablets. The label states 60 tablets per package, distributed by Novadoz Pharmaceuticals LLC. The label includes storage instructions and manufacturer information, MSN Laboratories in India. It highlights that 10 mg strength is recommended only in ulcerative colitis and includes pharmacy dispensing guidance.*

FDA Label Image

Tofacitinib-5mg-28s-cntr (Tofacitinib 5mg 28s Cntr)

Label for Tofacitinib Tablets 5 mg film-coated oral tablets in a 28-count package. The label includes dispensing instructions for pharmacists and storage information. Manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. The label shows the NDC 72205-139-28 and barcode information.*

FDA Label Image

Tofacitinib-5mg-60s-cntr (Tofacitinib 5mg 60s Cntr)

Tofacitinib Tablets 5 mg film-coated tablets label from Novadoz Pharmaceuticals LLC. The label indicates prescription use with NDC 72205-139-60, contains 60 tablets, and includes storage instructions and manufacturer information for MSN Laboratories Private Limited, India. It also has a barcode and pharmacist dispensing instructions.*

FDA Label Image

Tofacitinib-figure-01 (Tofacitinib Figure 01)

A chart depicting the pharmacokinetic parameters AUC and Cmax ratios relative to a reference for Tofacitinib under various intrinsic factors. The factors include weight categories (40 kg and 140 kg), age (80 years), sex (female), race (Asian, Black, Hispanic), and degrees of renal and hepatic impairment (mild, moderate, severe). Error bars represent 90% confidence intervals.*

FDA Label Image

Tofacitinib-figure-02 (Tofacitinib Figure 02)

A pharmacokinetic chart showing the ratio and 90% confidence intervals of various coadministered drugs relative to a reference. It includes parameters such as AUC and Cmax for drugs like Methotrexate, Midazolam, Levonorgestrel, Ethinyl Estradiol, and Metformin.*

FDA Label Image

Tofacitinib-figure-03 (Tofacitinib Figure 03)

A scatter plot chart titled 'Coadministered PK Ratio and 90% CI' depicting the ratio relative to reference for pharmacokinetic parameters AUC and Cmax. The x-axis displays the ratio scale from 0 to 2.5, while the y-axis lists coadministered drugs including Ketoconazole, Fluconazole, Rifampin, Methotrexate, Tacrolimus, and Cyclosporine. Data points with confidence intervals show the effect of each drug on AUC and Cmax compared to reference.*

FDA Label Image

Tofacitinib-figure-04 (Tofacitinib Figure 04)

A line graph depicting response rates with standard error bars over 0, 1, 3, and 6 months for Tofacitinib 5 mg twice daily versus placebo. The vertical axis shows response rates and the horizontal axis shows months. The graph includes notes on non-responder imputation and study measurement criteria regarding improvement in joint counts.*

FDA Label Image

Tofacitinib-figure-05 (Tofacitinib Figure 05)

A line graph comparing the response rates (%) over a 3-month period between Tofacitinib 5 mg BID and placebo. The x-axis represents visit months (0 to 3), and the y-axis represents response rate percentage (0% to 100%). Two lines show an increase in response rate over time, with Tofacitinib 5 mg BID consistently higher than placebo.*

FDA Label Image

Tofacitinib-figure-06 (Tofacitinib Figure 06)

A line graph showing response rates with standard error bars over a 16-week period for Tofacitinib 5 mg twice daily versus placebo. The y-axis represents Response Rate (+/- SE, %) and the x-axis shows Week. The graph compares treatment response trends between Tofacitinib and placebo groups across multiple time points.*

FDA Label Image

Tofacitinib-figure-07 (Tofacitinib Figure 07)

A line graph depicting the occurrence of disease flare percentages over time from week 18 to week 44. Two groups are shown: Tofacitinib 5 mg BID with 88 subjects and placebo with 85 subjects, with the Tofacitinib group showing a lower flare rate increase compared to placebo. The graph includes a statistical significance marker (p = 0.0007) near week 44.*

FDA Label Image

Tafacitinib-structure (Tofacitinib Structure)

Chemical structure of the active ingredient Tofacitinib, depicted alongside an associated molecular component, possibly a salt or hydrate form. The diagram shows detailed atomic connectivity for the molecule in two parts.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.